Cargando…
Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins
BACKGROUND: There exists a subpopulation of T2DM in whom first-line doses of statin are insufficient for optimally reducing LDL-C, representing a major risk of CVD. The RESEARCH study focuses on LDL-C reduction in this population along with modifications of the lipid profiles leading to residual ris...
Autores principales: | Sakamoto, Kentaro, Kawamura, Mitsunobu, Kohro, Takahide, Omura, Masao, Watanabe, Takayuki, Ashidate, Keiko, Horiuchi, Toshiyuki, Hara, Hidehiko, Sekine, Nobuo, Chin, Rina, Tsujino, Motoyoshi, Hiyoshi, Toru, Tagami, Motoki, Tanaka, Akira, Mori, Yasumichi, Inazawa, Takeshi, Hirano, Tsutomu, Yamazaki, Tsutomu, Shiba, Teruo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580589/ https://www.ncbi.nlm.nih.gov/pubmed/26398887 http://dx.doi.org/10.1371/journal.pone.0138332 |
Ejemplares similares
-
RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale
por: Inazawa, Takeshi, et al.
Publicado: (2013) -
Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects
por: Sakamoto, Kentaro, et al.
Publicado: (2017) -
Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
por: Rizzo, Manfredi, et al.
Publicado: (2011) -
Complementary Therapy to Target LDL Cholesterol: The Role of the Ezetimibe/Simvastatin Combination
por: Neal, Ryan C, et al.
Publicado: (2006) -
Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus
por: Olusi, Samuel O, et al.
Publicado: (2011)